Overview

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Type 1, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$15.32
Change (%) Stock is Down 0.41 (2.61%)
Volume28,892
Data as of 05/26/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $15.32 with a 52 week high of $20.74 and a 52 week low of $13.06.
Recent NewsMore >>
05/11/17
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
05/10/17
Audentes Therapeutics to Present At Upcoming Investor Conferences
05/08/17
Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.